Analyzing Cardiff Oncology (NASDAQ:CRDF) & Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology (NASDAQ:VIR) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Vir Biotechnology and Cardiff Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Cardiff Oncology	-6,238.17%	-73.97%	-60.40%

Risk & Volatility

Vir Biotechnology has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Insider & Institutional Ownership

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by company insiders. Comparatively, 7.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Vir Biotechnology and Cardiff Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$62.04 million	20.42	-$615.06 million	($3.92)	-2.35
Cardiff Oncology	$688,000.00	331.48	-$41.44 million	($0.94)	-4.74

Cardiff Oncology has lower revenue, but higher earnings than Vir Biotechnology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Vir Biotechnology and Cardiff Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0	1	5	0	2.83
Cardiff Oncology	0	0	3	0	3.00

Vir Biotechnology presently has a consensus price target of $34.83, suggesting a potential upside of 278.62%. Cardiff Oncology has a consensus price target of $10.33, suggesting a potential upside of 131.69%. Given Vir Biotechnology’s higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Cardiff Oncology.

Summary

Vir Biotechnology beats Cardiff Oncology on 9 of the 14 factors compared between the two stocks.

About Vir Biotechnology

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.